Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 3.6% – Here’s What Happened

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) was up 3.6% during trading on Tuesday . The stock traded as high as $278.30 and last traded at $278.25. Approximately 152 shares traded hands during trading, an increase of 418% from the average daily volume of 29 shares. The stock had previously closed at $268.55.

Bio-Rad Laboratories Stock Performance

The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. The stock has a fifty day simple moving average of $280.24 and a two-hundred day simple moving average of $294.64. The firm has a market capitalization of $7.51 billion, a P/E ratio of 9.97 and a beta of 1.02.

Bio-Rad Laboratories (NYSE:BIO.B) last posted its quarterly earnings results on Thursday, February 12th. The company reported $2.51 earnings per share (EPS) for the quarter. The firm had revenue of $693.20 million for the quarter. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.